Sermorelin: The Most Studied Peptide in the Compounding Pharmacy Catalog

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

Sermorelin is the only peptide in the integrative medicine catalog that combines four characteristics: it was once FDA-approved as a drug, it was voluntarily withdrawn from the market for commercial rather than safety reasons, it remains legally compoundable through 503A pharmacies, and it has a research base that runs back to the 1980s. These four facts together make sermorelin the most regulatorily settled and the most evidentially mature compound in the current peptide therapy market in the United States.

This article describes what sermorelin is, where it came from, what the research base supports, and what its current legal status looks like.

The molecule

Sermorelin is a synthetic peptide composed of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the anterior pituitary to release growth hormone. Endogenous GHRH is a 44-amino-acid peptide. The first 29 amino acids contain the full biological activity of the parent molecule, and the synthetic 29-amino-acid fragment functions as a GHRH analog.1

The compound's mechanism is well-characterized. Sermorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary, which triggers the same downstream signaling cascade as endogenous GHRH and produces a pulsatile release of growth hormone from the pituitary's existing pool. The relevant distinction here is between sermorelin, which stimulates the body's own growth hormone release, and synthetic recombinant human growth hormone (somatropin), which directly substitutes for endogenous growth hormone. The two compounds operate at different points in the regulatory axis.2

Sermorelin has a short pharmacokinetic half-life, on the order of 10 to 12 minutes after subcutaneous administration. The biological effect, however, is longer-lasting because the growth hormone released in response to sermorelin enters its own pulsatile clearance kinetics over the following hours.

The regulatory history

Sermorelin received FDA approval in 1990 under the brand name Geref, marketed by Serono. The original approved indications were as a diagnostic agent for the evaluation of growth hormone secretory function and, in a separate later approval, for the treatment of idiopathic growth hormone deficiency in children. The compound entered the US prescription market and remained available for over a decade.3

In 2008, Serono voluntarily withdrew Geref from the US market. The withdrawal was a commercial decision, not a safety or efficacy action. Public records indicate the withdrawal reflected the manufacturer's strategic priorities rather than any FDA action against the drug.4 The voluntary nature of the withdrawal is important to the compound's current regulatory status. Drugs that are voluntarily withdrawn for commercial reasons remain available through 503A compounding pharmacies under the terms of the Federal Food, Drug, and Cosmetic Act, because compounding pharmacies may use bulk drug substances that were the subject of an FDA-approved drug.5

After the Geref withdrawal, sermorelin moved into the 503A compounding pharmacy channel and gradually became one of the most commonly compounded peptides in integrative and longevity-oriented medical practice. The combination of established regulatory status, decades of clinical experience, and a recognized mechanism made it a preferred starting compound for physicians moving into peptide therapy.

What the research base supports

The sermorelin research literature spans both the pediatric growth hormone deficiency context (its original approved indication) and a broader adult literature on growth hormone axis function in older populations.

In the pediatric literature, sermorelin's effects on growth velocity and IGF-1 levels in children with idiopathic growth hormone deficiency are well-documented across multiple controlled trials. The compound's mechanism is consistent and predictable in this population.6

The adult literature is smaller and more variable. Several studies have examined the effects of GHRH analogs, including sermorelin and the closely related GHRH(1-29) variants, on body composition, sleep architecture, and growth hormone axis markers in older adults. The findings indicate that the GHRH receptor pathway remains responsive in many adults and that sermorelin produces measurable changes in IGF-1 and slow-wave sleep parameters in study populations.7

What the research base does not support, in the language the FDA reads as drug claims, is any specific indication or any outcome the compound treats, cures, or prevents. The published literature describes a peptide that interacts with the GHRH receptor and produces effects on biological markers downstream of that interaction. The literature does not establish sermorelin as a treatment for aging, sleep disorders, body composition outcomes, or any specific clinical condition in adult populations. The integrative medicine use of sermorelin in adults proceeds on the basis of the mechanistic rationale and the available physiological data, not on the basis of FDA-approved indications for those uses.

The off-label and 503A use cases

503A compounding pharmacies prepare custom medications based on individual physician prescriptions. A physician evaluates a patient, identifies a clinical rationale for treatment, prescribes a compounded preparation, and the pharmacy fills the prescription. The legal frame is the physician-patient-pharmacy relationship rather than a marketed indication.

For sermorelin specifically, the typical 503A use pattern is a physician evaluation of growth hormone axis function (often including IGF-1 testing), followed by a sermorelin prescription if the physician determines that the GHRH receptor pathway is an appropriate intervention target. Compounded sermorelin preparations are typically administered by subcutaneous injection in a pulsatile pattern that approximates endogenous GHRH release.

This is the same use pattern that existed when sermorelin was the FDA-approved Geref. The regulatory frame changed when the brand was withdrawn. The clinical practice changed less.

Sermorelin compared to other GHRH-axis compounds

The 503A peptide catalog includes several GHRH-axis compounds with different pharmacokinetic and mechanistic profiles. A reader trying to understand where sermorelin sits among them benefits from a brief comparison.

Tesamorelin (FDA-approved as Egrifta) is a longer-acting GHRH analog with a modification (trans-3-hexenoyl attachment) that increases its plasma stability. Tesamorelin is approved for HIV-associated lipodystrophy. Its use in non-approved contexts is off-label.

CJC-1295 is a synthetic GHRH analog modified with a drug affinity complex that binds to serum albumin and extends the compound's half-life dramatically, in some formulations to several days. CJC-1295 was on the 2023 FDA Category 2 list and is not currently compoundable.

Ipamorelin is a growth hormone secretagogue receptor agonist, not a GHRH analog. It acts on a different receptor pathway (the ghrelin/GHSR pathway) to stimulate growth hormone release. Ipamorelin was also on the Category 2 list.

Of these, sermorelin is the compound with the most settled regulatory status in the US and the most extensive published research base. The other GHRH-axis and growth hormone secretagogue compounds have their own research literatures and clinical use cases, but their current legal availability through 503A pharmacies is more constrained than sermorelin's.

Safety profile in the published literature

The sermorelin safety profile, as documented across the pediatric and adult clinical trial literature and the post-marketing period of Geref's availability, is favorable in the populations studied. The most common reported effects are injection-site reactions and headache. Hypoglycemia has been reported in some patients during diagnostic use at higher doses than typical compounded preparations. Serious adverse events are rare in the published reports.8

The safety database is necessarily anchored in the population for which sermorelin was studied. The pediatric growth hormone deficiency literature is well-characterized. The adult use database is smaller. Long-term safety data on chronic adult use in non-deficient populations is limited, because the compound was approved for shorter-duration use and the longer-term adult use that became common after the Geref withdrawal was not systematically tracked.

Current status in the US market

As of 2026, sermorelin is one of the peptides most commonly prescribed and compounded in US integrative medicine practice. Empower Pharmacy, Olympia Pharmacy, BellaVie Pharmacy, and several other large 503A and 503B compounding facilities maintain sermorelin in their formularies. The compound has not been the subject of recent FDA enforcement action because its regulatory status is settled in a way that the Category 2 peptides are not.9

The compound is also one of the peptides most likely to anchor the next phase of US peptide therapy as the broader market transitions from research-chemical distribution into physician-led prescription channels. Brands launching embedded telehealth-and-pharmacy models for peptide therapy in 2026 frequently include sermorelin as a foundation compound, both because of its evidentiary and regulatory maturity and because the integrative medicine community has decades of practical experience with it.

What a reader should retain from this article

Sermorelin is a 29-amino-acid GHRH analog with FDA approval history, voluntary withdrawal for commercial reasons, and current legal compoundability under Section 503A. Its mechanism is well-characterized at the GHRH receptor. Its research base is the most mature of any compound currently in the 503A peptide catalog. Its clinical practice patterns predate its move to the compounding channel and continue largely unchanged. Its safety profile, within the constraints of the populations studied, is favorable.

The compound also represents the regulatory and evidentiary tier that the broader peptide market is moving toward. The features that make sermorelin the easiest peptide to discuss editorially (FDA history, voluntary withdrawal, documented research, settled compounding status) are the features the FDA's July 2026 PCAC review will be evaluating for the larger set of compounds under consideration. The market will likely have more compounds with sermorelin-like regulatory profiles after the review concludes. For now, sermorelin is the reference point.

Footnotes

1. Thorner MO, Vance ML, Hartman ML, et al. "Physiological role of somatostatin on growth hormone regulation in humans." Metabolism. 1990;39(9 Suppl 2):40-42. Foundational summary of GHRH and somatostatin regulation of growth hormone release. [verify PMID]
2. Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
   
3. FDA approval record for Geref (sermorelin acetate) for injection. Original NDA approval 1990. [verify NDA number and reference link]
4. FDA Federal Register notice of voluntary withdrawal of Geref from sale, 2008. [verify Federal Register citation]
5. Federal Food, Drug, and Cosmetic Act, Section 503A, governing bulk drug substances for use in compounding. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
   
6. Thorner MO, Rochiccioli P, Colle M, et al. "Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy." J Clin Endocrinol Metab. 1996;81(3):1189-1196. https://pubmed.ncbi.nlm.nih.gov/8772599/ [verify]
7. Vittone J, Blackman MR, Busby-Whitehead J, et al. "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men." Metabolism. 1997;46(1):89-96. https://pubmed.ncbi.nlm.nih.gov/9005976/ [verify]
8. Geref (sermorelin acetate) for injection. FDA-approved prescribing information from the period of US market availability. [verify reference link to archived label]
9. Frier Levitt, "Regulatory Status of Peptide Compounding in 2025," January 2026. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/
   
10. Examine.com summary entry for sermorelin and growth hormone-releasing peptides. https://examine.com